What Кваттрекс Treats: Main Uses and Benefits

Кваттрекс (Phenibut) may be part of symptomatic management, addressing conditions marked by increased discomfort or tension. In clinical practice within its countries of origin, it is used in situations involving certain distressing symptoms across neuropsychiatric and functional domains.

The medication is considered relevant in contexts marked by increased discomfort or tension, and helps address symptom clusters such as fear, inner tension, restlessness, and generalized worry. It is also applied across conditions presenting with systemic or localized discomfort, such as asthenia (fatigue/weakness), sleep disturbance caused by tension, and functional symptoms like vertigo from vestibular disorders. The medication may assist with communication difficulties like stuttering and tics, as part of supportive management.

It provides support that helps ease the overall symptom burden, supporting general well-being during symptomatic phases. This supportive role is often used during phases when symptoms become more noticeable, and may assist with maintaining functional stability during periods of psychological exhaustion or situational stress.

“This medication is commonly used to help with pre-operative anxiety before medical procedures and during acute episodes like motion sickness or alcohol withdrawal.”

Quick Fact: Relief for Neuropsychiatric Symptoms
Main Therapeutic Area	Emotional Stabilization (reducing tension and worry)
Supportive Area	Functional Support (addressing asthenia and certain balance/speech issues)
Contextual Use	Applied during phases of increased distress or discomfort (e.g., pre-operative, withdrawal)

Who Can and Cannot Use Кваттрекс?

The eligibility for using Кваттрекс (Phenibut) is defined by official regulatory documents from its licensing countries, setting explicit rules for eligible and excluded populations. Use is generally permitted for adults and certain pediatric groups who do not fall under any prohibition.

---

Absolute Contraindications

The medicine must not be used by individuals with a known hypersensitivity to Phenibut. It is strictly contraindicated during pregnancy and throughout the period of lactation (breastfeeding). Patients with significant organ dysfunction are also ineligible; this includes those with severe liver insufficiency or failure and individuals diagnosed with ulcerative lesions of the gastrointestinal tract.

---

Age-Related Rules and Restrictions

The official label establishes a minimum age for use. Кваттрекс is contraindicated for children under two years of age in some regulatory summaries, while other specific regional labels set the prohibition threshold at under eleven years of age.

---

Conditional Restrictions

Patients with general hepatic impairment may be eligible, but their use is restricted. Regulatory documents specify that prolonged treatment in this population requires specific caution and regular monitoring of liver function and blood count.

Interaction Map: Interactions with other medicines and products — official regulatory information for Кваттрекс

Interaction Scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions	CNS Depressants (including Anxiolytics, Sedatives, Opioids, Neuroleptics, Anticonvulsants); Gabapentinoids; Xanthine Derivatives (e.g., Bromotheophylline).
Specific interacting medicines (if explicitly listed)	Alcohol (Ethanol), Opiates, Bromotheophylline, Azlocillin, Pregabalin.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic Potentiation (additive CNS depressant effects); Altered Excretion/Clearance (increased excretion rate of co-administered medicines).
Timing-based interaction rules (if applicable)	None.
Population-specific interaction notes (if applicable)	None.
Interaction-related restrictions	Do not combine with Alcohol due to documented severe adverse outcome risks.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification (as defined in official documents)	Severe Risk (Pharmacodynamic potentiation with CNS depressants); Clinically Significant (Altered exposure/efficacy).
Regulatory basis (EMA / FDA / etc.)	Based on regulatory-aligned clinical and toxicological data summarized in government and intergovernmental sources.
Interaction-context constraints (as defined in official documents)	Prohibition of co-ingestion with alcohol and substantial caution/risk of severe outcome with other CNS depressants.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with Alcohol (Ethanol) is associated with the potentiation of central nervous system (CNS) depressant effects, resulting in an officially documented increased risk of severe adverse events, including respiratory depression and loss of consciousness.
• The effects are mutually potentiated with other CNS Depressants, including opioids, anxiolytics, and sedatives.
• The co-administration with Gabapentinoids (e.g., Pregabalin) may result in additive pharmacological effects that increase the risk for side effects.
• Кваттрекс may increase the excretion rate of certain medicines, such as Bromotheophylline, leading to a lower serum level and potential reduction in efficacy.
• The therapeutic efficacy of Кваттрекс can be decreased when used in combination with Azlocillin.

Connection to the overall interaction profile: The regulatory interaction structure for this product is defined primarily by pharmacodynamic potentiation, classifying combinations with CNS depressants as having a severe risk due to additive effects. Secondary to this are pharmacokinetic interactions that alter the clearance and lower the serum levels of certain co-administered medicines, formally documenting a potential reduction in their efficacy.

Кваттрекс is a derivative of gamma-aminobutyric acid (GABA) and phenylethylamine. The molecule targets the central nervous system (CNS), where its primary action involves GABA B receptor agonism. Binding to these G-protein coupled receptors activates intracellular inhibitory cascades, primarily through the suppression of adenylyl cyclase and subsequent cAMP synthesis reduction. This activation also facilitates the efflux of potassium ions by opening specific GABA B-linked channels, which induces postsynaptic membrane hyperpolarization and diminishes neuronal firing frequency.

Simultaneously, the compound acts as a positive allosteric modulator at the GABA A receptor complex, enhancing the inhibitory chloride ion conductance upon endogenous GABA binding. This dual GABAergic action significantly elevates inhibitory neurotransmission. The drug also interacts with the dopaminergic system, modifying the signaling flux in pathways regulated by dopamine. The sum of these molecular interactions results in system-level modulation characterized by reduced excitatory signaling and altered psychomotor activity.

How to Use Кваттрекс

Кваттрекс is used according to established administration and dosing patterns. The medication is formulated for oral administration as a 250 mg tablet, and must be taken before meals.

---

Standardized Dosing and Treatment Duration

Administration for standard adult use typically involves a dose of 250 mg to 500 mg taken three times per day. The highest approved single dose for an adult is 750 mg. For specific situational needs, such as the prevention of motion sickness, the protocol specifies a single administration of 250 mg to 500 mg taken one hour prior to the event. The treatment course is generally time-bound, typically lasting two to three weeks, with the possibility of extension up to four to six weeks.

Age-Specific and Procedural Rules

Specific dose limitations are stipulated for certain populations. The maximum single dose for older adults is restricted to 500 mg. For pediatric patients aged 8 to 14, the standard regimen is defined as 250 mg administered three times daily. Regarding procedural continuity, if one or more doses are missed, the instruction is to resume the previously prescribed dose schedule without increasing the amount to make up for the missed quantity. Furthermore, treatment following high-dose regimens (e.g., alcohol withdrawal) requires a gradual decrease in the daily dose during the tapering phase.

Research Evidence / Overview of Studies for Кваттрекс

Evidence for Use in Emotional Stabilization

Research exploring Кваттрекс (Phenibut) has historically focused on how symptoms like tension, fear, and generalized anxiety are measured. The available evidence includes clinical trials and reviews that have been conducted in the drug’s countries of origin since the 1960s. These trials examined patient populations presenting with fluctuating or unstable symptoms, including those with certain neurotic or psychosomatic conditions.

The outcomes that research monitored included changes in measured tension and anxiety scores, as well as research exploring patterns related to emotional stabilization and sleep disturbance linked to neurotic or psychosomatic states. Findings from these regional studies describe patterns observed in the studies during the defined study periods. However, because much of this evidence is historical and specific to certain regions, data that aligns with modern, globally accepted randomized trial standards remains limited.

---

Evidence for Functional and Situational Support

Research has also explored the evidence in contexts of functional imbalance and acute situational needs. This evidence includes studies that examined functional symptoms like asthenia (physical or mental fatigue), specific functional disorders, and the monitoring of outcomes related to functional imbalance, such as vertigo. The compound was also evaluated in research contexts involving temporary physiological imbalance, such as in acute situations like alcohol withdrawal.

Studies focusing on these scenarios monitored outcomes related to systemic or functional imbalance, such as measured changes in fatigue levels and balance function. In acute settings, research examined patterns related to episodic or acute symptom changes. The evidence available for these uses is generally derived from smaller, specialized trials and clinical observation reports, which contributes to the broader evidence landscape but provides limited insight into long-term or comparative research scenarios.

---

Long-Term Studies and Durability of Response

Information regarding the extended use of Кваттрекс and the durability of symptom patterns is not well characterized in international scientific literature. The clinical trials and research summaries that exist primarily describe patterns observed over defined, short-to-intermediate time intervals.

There is limited information for long-term outcomes regarding whether any measured changes persist over many months or years. The lack of standardized, long-term observational cohorts or maintenance trials means that there is limited information for long-term outcomes, and follow-up durations were limited in the bulk of the available research.

Common questions about Кваттрекс (FAQ)

Q: What is the main chemical ingredient in Кваттрекс?

A: Regulatory documents indicate that the main active pharmaceutical ingredient in Кваттрекс is ethylmethylhydroxypyridine succinate. This substance is a pyridine derivative, generally recognized for its ability to function as an antioxidant. The official formulation is intended to provide effects that support neurological function and help manage anxiety.

Q: How long does Кваттрекс usually take to start working or show noticeable effects?

A: Official product information shows that the medicine is absorbed relatively quickly; its time to maximum concentration (Tmax) in the blood is typically between 0.46 and 0.5 hours after administration. The rapid absorption suggests that the substance is quickly available in the body; however, the actual onset of noticeable clinical effects can vary between individuals.

Q: What are the common medical conditions Кваттрекс is officially indicated to treat?

A: According to the official product information, Кваттрекс is indicated for various conditions, primarily those related to neurological and vascular function. These include treating the consequences of acute cerebral circulation disorders, mild traumatic brain injury, and encephalopathy (a type of brain disease). It is also approved for neurosis-like and anxiety states, and for use in treating acute alcohol withdrawal syndrome.

Q: Is it safe to use Кваттрекс for patients with diagnosed glaucoma?

A: Official regulatory documents do not list glaucoma as a specific contraindication (a condition that strictly forbids use) for Кваттрекс. Contraindications usually pertain to severe liver or kidney failure. The choice to prescribe this medication for patients with glaucoma requires assessment by a healthcare professional, taking the individual's full medical history into account.

Q: Can I take Кваттрекс if I also have a history of bronchial asthma?

A: Regulatory information indicates that bronchial asthma is not listed as an absolute contraindication for using this medicine. Contraindications for Кваттрекс generally involve acute allergic reactions or severe organ failure. A healthcare provider is required to evaluate the overall risks and benefits for any patient with a history of asthma before determining if this medication is appropriate.

Q: What are the recommended uses for Кваттрекс outside of the main neurological indications, such as in cardiology or internal medicine?

A: Official product information focuses mainly on neurological and mental health indications, such as anxiety and encephalopathy. However, official information also indicates its use in the comprehensive treatment of coronary heart disease (ischemic heart disease). The inclusion of coronary heart disease in the treatment scope shows its relevance to conditions affecting both neurological and circulatory systems, consistent with the official indications.

Official Storage and Disposal Requirements

Official regulatory documents define the mandatory conditions for storing and disposing of Кваттрекс (Quattrex) to ensure product stability and safety. These requirements are strictly label-based and must be followed.

Storage Conditions

Requirement	Official Statement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep the product in its original container to protect it from moisture and light. Do not freeze.
Child Safety	Must be stored out of the sight and reach of children.
Stability	Do not use the medicine after the expiration date printed on the packaging.

Disposal Rules

Disposal must align with environmental regulations. Patients should use a community drug take-back program to dispose of unused or expired product. The product label prohibits flushing the medication down a sink or toilet to avoid environmental contamination, unless specifically instructed otherwise by the regulatory source.